Glaukos (NYSE:GKOS) Director Sells $536,350.00 in Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the sale, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. This trade represents a 12.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $109.00 on Friday. The company has a 50-day simple moving average of $91.77 and a 200-day simple moving average of $92.76. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The company has a market cap of $6.26 billion, a PE ratio of -70.78 and a beta of 0.69. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The firm had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same period last year, the company earned ($0.28) EPS. The firm’s quarterly revenue was up 38.1% on a year-over-year basis. On average, equities analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. Citigroup increased their price objective on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday. BTIG Research boosted their target price on shares of Glaukos from $104.00 to $116.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Needham & Company LLC raised their price target on shares of Glaukos from $117.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Stifel Nicolaus set a $115.00 price objective on shares of Glaukos in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $120.62.

Hedge Funds Weigh In On Glaukos

Hedge funds and other institutional investors have recently bought and sold shares of the stock. LPL Financial LLC increased its holdings in shares of Glaukos by 25.1% in the 1st quarter. LPL Financial LLC now owns 15,775 shares of the medical instruments supplier’s stock worth $1,553,000 after acquiring an additional 3,163 shares during the period. Nuveen LLC acquired a new position in Glaukos during the 1st quarter valued at about $31,474,000. HighTower Advisors LLC grew its position in Glaukos by 12.9% in the 1st quarter. HighTower Advisors LLC now owns 3,722 shares of the medical instruments supplier’s stock worth $366,000 after purchasing an additional 424 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in shares of Glaukos in the first quarter valued at approximately $207,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Glaukos by 174.9% during the first quarter. Russell Investments Group Ltd. now owns 38,393 shares of the medical instruments supplier’s stock valued at $3,779,000 after buying an additional 24,428 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.